Loading...
Market
Which company will be next to receive FDA approval for a chemotherapy-free cancer treatment by August 2025?
2
Resolution / Starting Odds
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
FDA approval announcements and press releases from pharmaceutical companies
Story
FDA Approves J&J's RYBREVANT® and LAZCLUZE™ for EGFR-Mutated Lung Cancer
Aug 20, 2024, 11:18 AM
The U.S. Food and Drug Administration (FDA) has granted approval to Johnson & Johnson's chemotherapy-free combination therapy for treating a specific type of non-small cell lung cancer. The treatment, which includes RYBREVANT® (amivantamab-vmjw) and LAZCLUZE™ (lazertinib), is designed as a first-line option for patients with EGFR-mutated advanced lung cancer. This marks Johnson & Johnson's first FDA approval for a chemotherapy-free lung cancer treatment.
View original story
Similar markets
Johnson & Johnson • 25%
Pfizer • 25%
AstraZeneca • 25%
Roche • 25%
Adaptimmune (Afami-cel) • 25%
Checkpoint Therapeutics (Cosibelimab) • 25%
Mirati Therapeutics (Adagrasib-Cetuximab) • 25%
Other • 25%
Afami-cel • 25%
Cosibelimab • 25%
Adagrasib-Cetuximab • 25%
Other • 25%
Merck & Co. • 25%
AstraZeneca • 25%
Roche • 25%
Other • 25%
iTeos Therapeutics • 25%
GSK • 25%
Another company • 25%
No approval by end of 2025 • 25%
Pfizer • 25%
Roche • 25%
AstraZeneca • 25%
Other • 25%
Mesothelioma • 25%
Lung Cancer • 25%
Breast Cancer • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Pfizer • 25%
Novartis • 25%
Roche • 25%
Other • 25%
